Durvalumab + oleclumab for liposarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Nov 2020: Trial started, NCT04668300
  2. 16 Dec 2020: Trial registered, NCT04668300

The trials

NCT04668300: Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma

State
Under way
Phase
Phase 2
People
75 planned
Started
26 Nov 2020
Primary completion
30 Jun 2027
Arms
Treatment (oleclumab, durvalumab)
Results
None posted
  1. 26 Nov 2020: Trial started
  2. 16 Dec 2020: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.